Home › Funds › K2 PRINCIPAL FUND, L.P. › NKTR
K2 PRINCIPAL FUND, L.P. position in NKTR
NEKTAR THERAPEUTICS · Health Care
K2 PRINCIPAL FUND, L.P. reported holding 106,939 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$6.5M, representing 0.77% of its reported portfolio and ranking #47 among its reported holdings. K2 PRINCIPAL FUND, L.P. has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How K2 PRINCIPAL FUND, L.P.'s NKTR position evolved
K2 PRINCIPAL FUND, L.P. first disclosed a stake in NKTR in Q2 2026 at 25,000 shares (US$1.7M). The position peaked in Q3 2026 at 106,939 shares, worth US$6.5M. Across 2 filings, K2 PRINCIPAL FUND, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 106,939 shares valued at US$6.5M — an increase of 81,939 shares quarter over quarter.. Notable position changes include a 328% increase in Q3 2026 (shares fell 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 25.00K | $1.75M | New |
| Q3 2026 | 106.94K | $6.47M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 56 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K sh · $50.54M · Q2 2026
- Prosight Management, LP 785.00K sh · $47.53M · Q3 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K sh · $32.93M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K sh · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K sh · $17.05M · Q2 2026
- 22NW, LP 281.12K sh · $17.02M · Q3 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $16.75M · Q2 2026
More on K2 PRINCIPAL FUND, L.P.
FAQ
How long has K2 PRINCIPAL FUND, L.P. held NKTR?
K2 PRINCIPAL FUND, L.P. has disclosed NKTR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is K2 PRINCIPAL FUND, L.P.'s current position in NKTR?
As of Q3 2026, K2 PRINCIPAL FUND, L.P. holds 106.94K shares of NKTR (NEKTAR THERAPEUTICS), valued at $6.47M, representing 0.77% of its reported portfolio and ranking #47.
Has K2 PRINCIPAL FUND, L.P. been buying or selling NKTR?
In the latest 13F filing (Q3 2026), K2 PRINCIPAL FUND, L.P. increased its position in NKTR. The position peaked in Q3 2026 at 106.94K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.